Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Aug 30, 2021 10:15pm
187 Views
Post# 33786273

RE:Bozzie?

RE:Bozzie?

Makes sense...

Fresenius and DaVita duking it out on dialysis clinics ( 2500 clinics vs 2800)

No one owns the Home Dialysis market ( yet)... but it is the next high growth area. Both know it. 

Davita not that impressed with the relatively newly approved Outset pump ... so they are forced to buy more of the NXStage equipment than they would like ( Effectively from their competitor Fresenius)   Only two approved Home Dialysis equipment makers ( so far) 

Spectral's Dialco could change all that. 

My " gut" says Fresenius would not be allowed to acquire Dialco... but DaVita might. 

Then there is the question of whether Baxter wants back into the HHD market ( reconsidered now given Covid and a new game-changer upstart)

Hmmmm!?!?!

MM 

<< Previous
Bullboard Posts
Next >>